International Off-Patent Industry's Wishlist For WHO Pandemic Accord
Executive Summary
As the WHO seeks input on a global accord to strengthen pandemic preparedness, the IGBA has provided suggestions from the off-patent industry ahead of a key step in the drafting process later this month.
You may also be interested in...
All Biosimilars Interchangeable? FDA Backs Switching With Spotlight On Science
In meta-analyses of biosimilar switching studies, FDA researchers found ‘zero difference in the risk of death, serious adverse events, and treatment discontinuations between participants who switched between biosimilars and reference products and participants who did not switch.’
Taking Control Of Our Destiny: Biocon Biologics CEO Tambe Celebrates European Viatris Integration
With Biocon Biologics having previously integrated its acquisition of Viatris’s biosimilars business in emerging markets and North America, the firm has now completed integration in Europe. In an exclusive interview, CEO Shreehas Tambe tells Generics Bulletin what this means for the company and reveals the opportunities it perceives ahead.
All Biosimilars Interchangeable? FDA Backs Switching With Spotlight On Science
In meta-analyses of biosimilar switching studies, FDA researchers found “zero difference in the risk of death, serious adverse events, and treatment discontinuations between participants who switched between biosimilars and reference products and participants who did not switch.”